GIM
NVO

Glenmede Investment Management’s Novo Nordisk NVO Stock Holding History

Glenmede Investment Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$9.06M Buy
163,298
+25,308
+18% +$1.48M 0.04% 371
2025
Q2 		$9.52M Buy
+137,990
New +$9.39M 0.05% 362

Other funds holding NVO

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Glenmede Investment Management's NVO Position: Q3 2025 in Review

Glenmede Investment Management increased its Novo Nordisk (NVO) stake by 18% in Q3 2025, buying an estimated $1.48M and bringing the position to 163,298 shares worth $9.06M. The position accounts for 0.04% of the portfolio, ranked #371.

Glenmede Investment Management first reported a position in NVO in Q2 2025 and has held it in 2 quarters since. The position peaked at $9.52M in Q2 2025. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

  • Glenmede Investment Management held 163,298 shares of Novo Nordisk worth $9.06M as of Q3 2025.
  • Glenmede Investment Management bought 25,308 Novo Nordisk shares in Q3 2025, an estimated $1.48M.
  • Novo Nordisk made up 0.04% of Glenmede Investment Management's portfolio in Q3 2025, its #371 holding.
  • Glenmede Investment Management first reported a position in Novo Nordisk in Q2 2025 and has held it in 2 quarters since.
  • Glenmede Investment Management's Novo Nordisk position peaked at $9.52M in Q2 2025.
  • 1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.